Clinical trials: Renal Transplant Recipient
CMV Disease
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients.
- Trial name
- NCT03443869
- Testing
- Letermovir, Valganciclovir, Acyclovir (ACV)
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
Short-term Graft Function, Metabolic Effects
Amino Acid Infusion in Kidney Transplant Recipients
The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.
- Conditions
- Short-term Graft Function, Metabolic Effects, Nutritional Effect, Immunological &Amp; Inflammatory Markers
- Trial name
- AID-KT (NCT06929637)
- Testing
- Infusion Therapy, Saline solution infusion
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- University Hospital, Martin
Kidney Transplantation
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
- Trial name
- NCT01820572
- Testing
- Belatacept, Tacrolimus, Cyclosporine
- Where
- 117 sites in United States, Argentina and 8 more
- Volunteers
- 446 people
- Sponsor
- Bristol-Myers Squibb
Transplantation, Kidney, Graft Occlusion, Vascular
GFR Measurement With Contrast-enhanced Dynamic MRI
The aim of the study is to optimize and validate this MR-based GFR measurement in patients with a renal transplant, compared with the reference method, the Cr51- EDTA method: to select the most accurate combination of…
- Trial name
- IREN (NCT00614081)
- Testing
- Contrast-enhanced dynamic MRI
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
To evaluate the safety of long-term administration of sirolimus oral solution for up to 5 additional years, or until the tablet formulation is commercially available (whichever occurs first) in solid organ transplant recipients…
- Trial name
- NCT00037531
- Testing
- Sirolimus (RAPAMUNE)
- Where
- 20 sites in United States, Canada
- Volunteers
- 769 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Allograft Injury
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
The main purpose of the study is to investigate the safety and tolerability of repeat dosing with zampilimab in kidney transplant recipients with deteriorating kidney function associated with chronic allograft injury (CAI).
- Trial name
- NCT04335578
- Testing
- Zampilimab
- Where
- 5 sites in Australia, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- UCB Biopharma SRL
Cytomegalovirus Infection
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring…
- Trial name
- LUCY-1 (NCT06334497)
- Testing
- Letermovir, Valganciclovir
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant
A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.
This study is being done to collect blood and bone marrow samples for biologic studies of antibody producing cells. Donor specific antibodies can cause damage to the kidneys after they are transplanted.
- Trial name
- NCT00275717
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Kidney Diseases
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
- Trial name
- NCT00407160
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Kidney Disease
Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving induction therapy with cyclosporin (CsA, Neoral) and Rapamune® followed by CsA dose reduction and…
- Trial name
- NCT00248313
- Testing
- Rapamune®
- Volunteers
- 470 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Renal Transplant Recipient
Abatacept Conversion in Kidney Transplantation
This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous…
- Trial name
- NCT04955366
- Testing
- Belatacept, Abatacept
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Kidney Transplantation, Antibody-mediated Rejection
CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients
This multicenter, prospective, single-arm exploratory study evaluates the efficacy and safety of a novel sequential regimen for chronic active antibody-mediated rejection (caABMR) in kidney transplant recipients: single-dose CD38…
- Trial name
- CAZA (NCT07718308)
- Testing
- CD38, Azathioprine (AZA), Standard Triple Immunosuppression Maintenance
- Volunteers
- 20 people
- Sponsor
- wujianyong
Kidney Transplantation
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of a single intravenous dose of ASP8597 in kidney transplant recipients.
- Trial name
- NCT01442337
- Testing
- ASP8597
- Where
- 19 sites in United States
- Volunteers
- 21 people
- Sponsor
- Astellas Pharma Inc
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant; Complications, CMV
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
This study is being done to compare the effectiveness of de novo Letermovir versus valganciclovir in preventing the development of cytomegalovirus viremia or symptomatic disease in African American kidney transplant recipients…
- Trial name
- NCT06001320
- Testing
- Letermovir 480 mg once daily, Historical/Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Kidney Transplant, Immunosuppression
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
This is an unblinded, randomized, four-arm interventional research study enrolling patients who are undergoing kidney transplantation.
- Conditions
- Kidney Transplant, Immunosuppression, Allograft
- Trial name
- NCT05423496
- Testing
- KidneyCare, steroid, MMF
- Sponsor
- CareDx
Kidney Transplantation, Chronic Kidney Failure
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in…
- Trial name
- NCT00472082
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Kidney Transplantation
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and potential for CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate of acute rejection prophylaxis and…
- Trial name
- NCT02217410
- Testing
- CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF)
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Antibody-Mediated Rejection (AMR)
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure.
- Trial name
- NCT07613359
- Testing
- Mezagitamab
- Where
- 35 sites in United States, China and 3 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute